CN110721306A - Composition for treating kidney deficiency - Google Patents
Composition for treating kidney deficiency Download PDFInfo
- Publication number
- CN110721306A CN110721306A CN201911193077.4A CN201911193077A CN110721306A CN 110721306 A CN110721306 A CN 110721306A CN 201911193077 A CN201911193077 A CN 201911193077A CN 110721306 A CN110721306 A CN 110721306A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- composition
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a composition for treating kidney deficiency, which comprises traditional Chinese medicine active ingredients and oyster peptide; the traditional Chinese medicine effective components comprise the following raw material components in parts by weight: 30-60 parts of epimedium extract, 5-20 parts of American ginseng extract, 2-10 parts of cynomorium songaricum extract, 2-10 parts of cistanche extract, 2-10 parts of morinda officinalis extract and 2-10 parts of polyrhachis vicina extract; the content of oyster peptide in the composition is more than or equal to 20 wt%. The composition has the advantages of quick response, obvious curative effect, safe formula and no toxic or side effect when used for treating kidney deficiency.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a composition for treating kidney deficiency.
Background
Kidney deficiency refers to the deficiency of kidney essence, qi, yin and yang. There are many kinds of kidney deficiency, and the most common of them is kidney yin deficiency and kidney yang deficiency. The symptoms of kidney deficiency mainly include lumbago accompanied with soreness and weakness, dizziness and tinnitus, easy kneading and pressing, weakness of legs and knees, even more severe when people feel tired, and alleviation when people lie down, with recurrent attacks. The kidney deficiency is caused by many reasons, mainly including the following: 1) the modern society is still cool in competition, and the excessive pressure causes most people to bear huge physical and mental pressure, fatigue and energy decline, so that insomnia, anorexia, hypodynamia, dysphoria and splenic dysphoria appear, and further, the kidney deficiency caused by neurasthenia and the like and the kidney deficiency caused by brain deficiency symptoms are caused. 2) Long-term bad living habits and frequent sexual life can directly damage the kidney essence of human body, resulting in kidney deficiency. 3) The kidney is damaged due to the over fatigue caused by careless daily life, smoking and alcohol drinking. 4) The office group has the advantages that the brain labor is increased, the physical labor is reduced, the office group is seated in the office, exercise is lacked, the heart and lung functions are low, effective and sufficient nutrition and oxygen supply to various important organs of the body cannot be guaranteed, and people are in a sub-health state to cause kidney deficiency.
At present, the common western medicines with the functions of tonifying kidney and strengthening yang and relieving physical fatigue on the market are not the primary and secondary symptoms, have large side effects, slow effect taking and unobvious curative effect of the traditional Chinese medicine active ingredients or the traditional Chinese medicines, and have poor long-term use effect and high consumption of the health-care food.
Disclosure of Invention
Compared with the conventional traditional Chinese medicine therapy, the composition for treating kidney deficiency has the advantages of quick response, obvious curative effect, safe formula and no toxic or side effect.
In order to achieve the above objects, a composition for treating kidney deficiency comprises Chinese medicinal active ingredients and oyster peptide; the traditional Chinese medicine effective components comprise the following raw material components in parts by weight: 30-60 parts of epimedium extract, 5-20 parts of American ginseng extract, 2-10 parts of cynomorium songaricum extract, 2-10 parts of cistanche extract, 2-10 parts of morinda officinalis extract and 2-10 parts of polyrhachis vicina extract; the content of oyster peptide in the composition is more than or equal to 20 wt%.
Preferably, the content of the oyster peptides in the composition is 40-50 wt%.
Preferably, the oyster peptide has a small molecule content of 65 wt% or more.
Preferably, the effective components of the traditional Chinese medicine comprise the following raw material components in parts by weight: 40 parts of epimedium extract, 10 parts of American ginseng extract, 5 parts of cynomorium songaricum extract, 5 parts of cistanche extract, 5 parts of morinda officinalis extract and 5 parts of polyrhachis vicina extract.
Preferably, the effective components of the traditional Chinese medicine comprise the following raw material components in parts by weight: 30 parts of epimedium extract, 5 parts of American ginseng extract, 2 parts of cynomorium songaricum extract, 2 parts of cistanche extract, 2 parts of morinda officinalis extract and 2 parts of polyrhachis vicina extract.
Preferably, the effective components of the traditional Chinese medicine comprise the following raw material components in parts by weight: 60 parts of epimedium extract, 20 parts of American ginseng extract, 10 parts of cynomorium songaricum extract, 10 parts of cistanche extract, 10 parts of morinda officinalis extract, 10 parts of polyrhachis vicina extract and 80 parts of oyster peptide.
Preferably, the effective components of the traditional Chinese medicine comprise the following raw material components in parts by weight: 45 parts of epimedium extract, 12 parts of American ginseng extract, 6 parts of cynomorium songaricum extract, 6 parts of cistanche extract, 6 parts of morinda officinalis extract, 6 parts of polyrhachis vicina extract and 55 parts of oyster peptide.
Preferably, the extraction ratio of the epimedium extract, the cynomorium songaricum extract, the cistanche extract, the morinda officinalis extract and the polyrhachis vicina extract is 10: 1; the content of panaxoside in the American ginseng extract is more than or equal to 80 wt%.
Compared with the prior art, the invention has the advantages and positive effects that: the invention provides a composition for treating kidney deficiency, the composition has proper raw material compatibility, can play roles of strengthening spleen and tonifying kidney, tonifying qi and activating blood and improving immunity, and the oyster peptide is compounded with the effective components of the traditional Chinese medicine, so that the drug effect exertion of the effective components of the traditional Chinese medicine for treating kidney deficiency can be remarkably accelerated.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
A composition for treating kidney deficiency comprises Chinese medicinal effective components and oyster peptide; the traditional Chinese medicine effective components comprise the following raw material components in parts by weight: 30-60 parts of epimedium extract, 5-20 parts of American ginseng extract, 2-10 parts of cynomorium songaricum extract, 2-10 parts of cistanche extract, 2-10 parts of morinda officinalis extract and 2-10 parts of polyrhachis vicina extract; the content of oyster peptide in the composition is more than or equal to 20 wt%.
Specifically, the extraction purity of the epimedium extract, the cynomorium songaricum extract, the cistanche extract, the morinda officinalis extract and the polyrhachis vicina extract is 10: 1; the content of panaxoside in the American ginseng extract is more than or equal to 80 wt%; the content of small molecules of the oyster peptides is more than or equal to 65 wt%.
The above extracts are commercially available. In addition, the process of extracting the extract from the Chinese herbal medicine has been widely used, and as is well known to those skilled in the art, various extracts involved in the present invention can be obtained by using the existing extraction process. For example, the epimedium extract can be obtained by the following process: raw material → water extraction → concentration → extract → solvent extraction → extract concentration → extract → spray drying → pulverization, mixing, packaging → product; the American ginseng extract, the cynomorium songaricum extract, the cistanche extract and the morinda officinalis extract can be obtained by the following processes: raw material → water extraction → concentration → extract → spray drying → pulverization, mixing and packaging → product; the polyrhachis vicina roger extract can be obtained by the following process: raw materials → water extraction → percolation → reflux → distillation → precipitation → filtration → concentration → spray drying → pulverization, mixing, packaging → product.
The composition of the above embodiments can be made into various dosage forms such as tablets, granules, pills and the like by a conventional method, for example, the preparation method of the pills comprises the following steps: mixing herba Epimedii extract, radix Panacis Quinquefolii extract, herba Cynomorii extract, Cistanchis herba extract, radix Morindae officinalis extract, polyrhachis vicina Roger extract, and Concha Ostreae peptide to obtain effective component mixed powder, adding appropriate amount of adjuvants such as starch, dextrin, and mannitol, mixing, making soft mass, and making pill.
The action and the effect of the selected raw materials are as follows:
herba epimedii: the Chinese medicinal composition has pungent, sweet and warm taste, and can walk liver and kidney meridians, is a key medicine for tonifying the vital gate, benefiting vital essence and qi, strengthening bones and muscles, tonifying kidney and strengthening yang, and is clinically used for treating male impotence, spermatorrhea, premature ejaculation, urinary incontinence, female infertility and other symptoms; modern researches show that the epimedium contains icariin, volatile oil, ceryl alcohol, phytosterol, tannin, vitamin E and other components, can excite sexual function, has the effect of promoting semen secretion on animals, has the effects of reducing blood pressure, reducing blood sugar, promoting urination, relieving cough and eliminating phlegm, and has the effects of resisting aging, resisting tumors and the like;
american ginseng: sweet and slightly bitter in taste, has the effects of tonifying qi and yin, clearing heat and promoting fluid production, and is used for treating deficiency of qi and yin, internal heat, cough, asthma, phlegm and blood, deficiency heat, vexation and fatigue, diabetes, dry mouth and throat, tonifying lung yin, clearing deficiency fire, promoting fluid production and quenching thirst, and treating chronic cough due to lung deficiency, blood loss, dry throat and thirst, deficiency heat and vexation and fatigue;
and (3) locking the positive: has effects in invigorating kidney, replenishing vital essence, moistening dryness, and can be used for treating sexual impotence, spermatorrhea, soreness of waist and knees, constipation due to intestinal dryness, paralysis, and sexual hypofunction;
cistanche deserticola: sweet and salty taste, warm nature, tonifying kidney yang, benefiting essence and blood, and moistening intestinal tract; it is mainly used for treating kidney yang deficiency, impotence due to essence and blood deficiency, spermatorrhea, whitish and turbid urine, frequent micturition, dribbling urination, lumbago, leg weakness, tinnitus, blurred vision, menstrual cycle, infertility due to cold womb, constipation due to intestinal dryness;
morinda officinalis: sweet and pungent taste, mild nature, kidney yang tonifying, muscle and bone strengthening, rheumatism eliminating, sexual impotence and spermatorrhea, infertility due to cold womb, menoxenia, cold pain in lower abdomen, arthralgia due to wind-dampness, and flaccidity of tendons and bones;
polyrhachis vicina roger: the ant health-care food contains more than fifty nutrient components required by a human body, twenty-eight free amino acids, multiple vitamins and multiple trace elements required by the human body, can balance nutrition, balance organisms, treat different diseases simultaneously and have dual purposes of medicine and food, integrates the functions of ant nourishing nutrition, tonifying spleen and kidney, clearing and activating the channels and collaterals, tonifying qi and activating blood, bidirectionally regulating immunity, resisting viruses, resisting inflammation and easing pain, calming and the like, prevents and treats deficiency-type difficult and complicated diseases such as rheumatism, rheumatoid, hepatitis B, cough and asthma, diabetes and the like, balances the nutrition and balances the organisms, improves immunity and disease resistance, improves endurance, resists fatigue and enhances sexual function, and has health-care and health-care effects of delaying senility and the like;
oyster shell: has the functions of improving the male serum testosterone level, regulating blood fat, inhibiting platelet aggregation, improving hyperglycemia symptoms, improving human immunity, promoting metabolism and the like, and also has certain effects of resisting cancer and preventing cancer cell diffusion; the oyster peptide is prepared by applying peptide molecular biotechnology to oyster processing and performing enzymolysis. The micromolecule oligopeptide formed by the preparation method completely reserves the original nutrients such as vitamins, trace elements, taurine and the like of the oysters, so that the oysters rich in nucleic acid can be absorbed by the human body more quickly than single amino acid or protein after being ingested by the human body, are absorbed by the human body more easily, have more important biological activity in the aspect of human metabolism, and can effectively improve the male serum testosterone level.
The composition provided by the embodiment has the advantages that the raw materials are properly matched, the effects of tonifying spleen and kidney, tonifying qi and activating blood, and improving immunity can be achieved, the kidney and tonifying yang can be realized, the composition is suitable for treating kidney deficiency, is suitable for body weakness caused by long-term illness, cold limbs and spontaneous perspiration, impotence and spermatorrhea, deficiency of primordial qi, kidney deficiency and impotence, no obvious toxic or side effect is found in research, and the safety is high. The composition of the invention uses the oyster peptide to compound the effective components of the traditional Chinese medicine, can remarkably accelerate the drug effect exertion of the effective components of the traditional Chinese medicine for treating kidney deficiency, is administrated by patients with kidney deficiency according to 0.06g/kg every day, improves the symptoms of the patients taking the composition for 8-48 h, and has quick effect. Compared with the conventional traditional Chinese medicine therapy, the traditional Chinese medicine composition has the advantages of quick response, obvious curative effect, safe formula and no toxic or side effect.
Example 1
A composition for treating kidney deficiency comprises traditional Chinese medicine active ingredients and oyster peptides, wherein the content of the oyster peptides is 20 wt%, and the traditional Chinese medicine active ingredients comprise the following raw material components in parts by weight: 30 parts of epimedium extract, 5 parts of American ginseng extract, 2 parts of cynomorium songaricum extract, 2 parts of cistanche extract, 2 parts of morinda officinalis extract and 2 parts of polyrhachis vicina extract.
The composition of this example was administered to patients with kidney deficiency at 0.06g/kg daily, and symptoms were improved in patients taking 2 days.
Example 2
The composition for treating kidney deficiency comprises traditional Chinese medicine effective components and oyster peptides, wherein the content of the oyster peptides is 40 wt%, and the traditional Chinese medicine effective components comprise the following raw material components in parts by weight: 60 parts of epimedium extract, 20 parts of American ginseng extract, 10 parts of cynomorium songaricum extract, 10 parts of cistanche extract, 10 parts of morinda officinalis extract and 10 parts of polyrhachis vicina extract.
The composition of the present example was administered to patients with kidney deficiency at a dose of 0.06g/kg per day for 12 hours to improve the symptoms.
Example 3
A composition for treating kidney deficiency comprises traditional Chinese medicine effective components and oyster peptides, wherein the content of the oyster peptides is 30 wt%, and the traditional Chinese medicine effective components comprise the following raw material components in parts by weight: 45 parts of epimedium extract, 12 parts of American ginseng extract, 6 parts of cynomorium songaricum extract, 6 parts of cistanche extract, 6 parts of morinda officinalis extract and 6 parts of polyrhachis vicina extract.
The composition of this example was administered to patients with kidney deficiency at a dose of 0.06g/kg per day, and symptoms were improved in patients who took 1 day.
Example 4
A composition for treating kidney deficiency comprises traditional Chinese medicine active ingredients and oyster peptides, wherein the content of the oyster peptides is 10 wt%, and the traditional Chinese medicine active ingredients comprise the following raw material components in parts by weight: 40 parts of epimedium extract, 10 parts of American ginseng extract, 5 parts of cynomorium songaricum extract, 5 parts of cistanche extract, 5 parts of morinda officinalis extract and 5 parts of polyrhachis vicina extract.
The composition of the embodiment is administrated to patients with kidney deficiency at 0.06g/kg daily, and the symptoms of the patients are improved after taking the composition for 8 days, so that the effect is fast.
The effective components of the traditional Chinese medicine of the embodiment are singly taken by a patient with kidney deficiency according to the dosage of 0.06g/kg every day, and the symptoms of the patient are improved after taking the traditional Chinese medicine for 8 days, so that the effect is fast.
The oyster peptide of the embodiment is singly taken by a patient with kidney deficiency according to the dosage of 0.06g/kg every day, and the symptoms of the patient are improved after the patient takes 6 days, thus the effect is fast.
Example 5
A composition for treating kidney deficiency comprises traditional Chinese medicine active ingredients and oyster peptides, wherein the content of the oyster peptides is 20 wt%, and the traditional Chinese medicine active ingredients comprise the following raw material components in parts by weight: 40 parts of epimedium extract, 10 parts of American ginseng extract, 5 parts of cynomorium songaricum extract, 5 parts of cistanche extract, 5 parts of morinda officinalis extract and 5 parts of polyrhachis vicina extract.
The composition of the embodiment is administrated to patients with kidney deficiency at 0.06g/kg daily, and the symptoms of the patients are improved after taking the composition for 2 days, and the effect is quick.
Example 6
A composition for treating kidney deficiency comprises traditional Chinese medicine effective components and oyster peptides, wherein the content of the oyster peptides is 30 wt%, and the traditional Chinese medicine effective components comprise the following raw material components in parts by weight: 40 parts of epimedium extract, 10 parts of American ginseng extract, 5 parts of cynomorium songaricum extract, 5 parts of cistanche extract, 5 parts of morinda officinalis extract and 5 parts of polyrhachis vicina extract.
The composition of the embodiment is administrated to patients with kidney deficiency at 0.06g/kg daily, and the symptoms of the patients are improved after taking the composition for 1 day, and the effect is quick.
Example 7
The composition for treating kidney deficiency comprises traditional Chinese medicine effective components and oyster peptides, wherein the content of the oyster peptides is 40 wt%, and the traditional Chinese medicine effective components comprise the following raw material components in parts by weight: 40 parts of epimedium extract, 10 parts of American ginseng extract, 5 parts of cynomorium songaricum extract, 5 parts of cistanche extract, 5 parts of morinda officinalis extract and 5 parts of polyrhachis vicina extract.
The composition of the embodiment is administrated to patients with kidney deficiency at 0.06g/kg daily, and the symptoms of the patients are improved after taking the composition for 12h, and the effect is fast.
Example 8
A composition for treating kidney deficiency comprises traditional Chinese medicine effective components and oyster peptides, wherein the content of the oyster peptides is 50 wt%, and the traditional Chinese medicine effective components comprise the following raw material components in parts by weight: 40 parts of epimedium extract, 10 parts of American ginseng extract, 5 parts of cynomorium songaricum extract, 5 parts of cistanche extract, 5 parts of morinda officinalis extract and 5 parts of polyrhachis vicina extract.
The composition of the embodiment is administrated to patients with kidney deficiency at 0.06g/kg daily, and the symptoms of the patients are improved after taking the composition for 8h, and the effect is fast.
Example 9
The composition for treating kidney deficiency comprises traditional Chinese medicine effective components and oyster peptides, wherein the content of the oyster peptides is 60 wt%, and the traditional Chinese medicine effective components comprise the following raw material components in parts by weight: 40 parts of epimedium extract, 10 parts of American ginseng extract, 5 parts of cynomorium songaricum extract, 5 parts of cistanche extract, 5 parts of morinda officinalis extract and 5 parts of polyrhachis vicina extract.
The composition of the embodiment is administrated to patients with kidney deficiency at 0.06g/kg daily, and the symptoms of the patients are improved after taking the composition for 8h, and the effect is fast.
Example 10 efficacy verification test
This example uses the compositions of examples 1 to 9 as test samples to perform efficacy verification tests.
In the experiment, the cortisol is used for inducing the deficiency of the kidney yang of a rat to cause erectile dysfunction, the active ingredients of the traditional Chinese medicine used in the embodiment 4 are used as a positive control 1, the active ingredients of the traditional Chinese medicine used in the embodiment 4 are used as a positive control 2, the oyster peptide is used as a positive control 3, the differences of the body weight and the male hormone indexes of the rat are compared, and the improvement effect of the tested sample of different embodiments on the erectile dysfunction of the rat is evaluated, and the specific experiment contents are as follows.
1. Principle of mold making
The cortisol model is characterized in that a certain amount of exogenous glucocorticoid is used for inhibiting ACTH release of anterior pituitary, so that steroid hormone secretion of adrenal cortex is reduced, animals are exhausted, and erectile dysfunction is caused.
2. Design of experiments
1) Route of administration and reasons for selection: the oral gavage administration is the same as the clinical administration route.
2) The administration frequency is as follows: the administration was 1 time per day.
3) Calculating the dosage of the medicine: the dose administered to the rats was 0.06g/kg, respectively.
4) Dose capacity: 1.7ml/100g rat.
5) Animal grouping: animals were randomized into 14 groups by weight: a normal control group, a model control group, a positive control group 1 (wanaco), a positive control group 2 (the effective ingredient of the traditional Chinese medicine in example 4), a positive control group 3 (oyster peptide), an example 1 group, an example 2 group, an example 3 group, an example 4 group, an example 5 group, an example 6 group, an example 7 group, an example 8 group, and an example 9 group, and 10 animals were assigned to each group.
3. Measurement method
140 SPF-grade SD male rats were divided into 5 groups at random according to body weight, and the groups were a normal control group, a model control group, a positive control group 1 (warfarin), a positive control group 2 (the effective ingredient of the traditional Chinese medicine in example 4), a positive control group 3 (oyster peptide), an example 1 group, an example 2 group, an example 3 group, an example 4 group, an example 5 group, an example 6 group, an example 7 group, an example 8 group, and an example 9 group.
The normal control group of the tested rats is fed with distilled water 25mg/kg per day, the other groups of the tested rats are fed with hydrocortisone 25mg/kg per day, then the normal control group and the model control group are fed with physiological saline with the same volume as the experimental group per day, the dose of the Wanaike tablet of the positive control group 1 is 8.33mg/kg, and the dose of the sample of the other experimental groups is 0.06 g/kg.
4. Experimental methods
140 SPF SD male rats were collected, and 130 of the rats were intramuscularly administered hydrocortisone 1 time per day, followed by administration of test samples 1 time for 14 consecutive days. 1h after the 14 th day of administration, weighing, taking blood from orbital venous plexus, separating serum, and measuring the content of testosterone (T) and Nitric Oxide (NO) in the serum.
5. Results of the experiment
TABLE 1 Effect on rat body weight, androgens and nitric oxide
Testosterone (T) is the main male hormone of men, and the physiological effects of testosterone (T) mainly comprise improving male activity, improving libido, promoting muscle tissue increase, promoting erythropoiesis and the like; nitric Oxide (NO) is an in vivo reporter molecule and effector molecule, and plays an important role in a number of systems, such as cardiovascular, neurological, immune, and male sexual function regulation. NO can dilate blood vessel, promote the dilation of penis sponge, and make blood quickly fill penis to erect. The application tests the content of serum testosterone (T) and Nitric Oxide (NO) in the serum of experimental mice, and the data in the table 1 show that:
(1) compared with the normal control group, the body weight of the rats in the model control group is reduced, but NO obvious difference exists, and the contents of testosterone (T) and Nitric Oxide (NO) in serum are obviously reduced.
(2) Except for the samples in the group of example 4, compared with the model control group and the positive control group 1 (the conventional medicine Wanaike), the samples in the other examples have obvious increasing tendency on the serum testosterone (T) and the Nitric Oxide (NO) contents of rats, namely when the content of the oyster peptide is more than or equal to 20 wt%, the composition in the embodiment of the application can obviously improve the serum testosterone (T) and the Nitric Oxide (NO) contents of the rats.
(3) According to the experimental results of the positive control group 2, the comparative example 4 and the example 9, under the condition that the traditional Chinese medicine extract formula is consistent, after the content of the oyster peptide is more than or equal to 20 wt%, the capacity of the composition of the example for enhancing the serum testosterone (T) and Nitric Oxide (NO) content of a rat is enhanced along with the increase of the content of the oyster peptide, and after the content of the oyster peptide is more than or equal to 50 wt%, the serum testosterone (T) and Nitric Oxide (NO) content of the rat is not changed along with the content of the oyster peptide.
In conclusion, the composition provided by the embodiment of the invention can improve the content of testosterone (T) and Nitric Oxide (NO) in the serum of a body, and is beneficial to improving male sexual dysfunction. When the content of the oyster peptides in the composition is more than or equal to 20 wt%, the action effect can be obviously improved, and when the content of the oyster peptides is within the range of 20-50 wt%, the drug effect of the composition shows an improvement trend along with the increase of the content of the oyster peptides. Meanwhile, the experimental results of comparative examples 4 to 9 show that the onset time of the composition of the present invention can be significantly shortened when the content of the oyster peptides is greater than or equal to 20 wt%, the onset time of the composition is shortened with the increase of the content of the oyster peptides when the content of the oyster peptides is within the range of 20 to 50 wt%, and the onset time of the composition is not changed with the content of the oyster peptides when the content of the oyster peptides is greater than 50 wt%.
The above description is only exemplary of the present invention and is not intended to limit the present invention in other forms, and any person skilled in the art may apply the above modifications or changes to the equivalent embodiments using the above disclosure as equivalent variations, but all simple modifications, equivalent variations and changes made to the above embodiments according to the technical spirit of the present invention may still fall within the protection scope of the present invention.
Claims (8)
1. A composition for treating kidney deficiency is characterized by comprising traditional Chinese medicine effective components and oyster peptide; the traditional Chinese medicine effective components comprise the following raw material components in parts by weight: 30-60 parts of epimedium extract, 5-20 parts of American ginseng extract, 2-10 parts of cynomorium songaricum extract, 2-10 parts of cistanche extract, 2-10 parts of morinda officinalis extract and 2-10 parts of polyrhachis vicina extract; the content of oyster peptide in the composition is more than or equal to 20 wt%.
2. The composition for treating kidney deficiency according to claim 1, wherein the content of oyster peptides in the composition is 40-50 wt%.
3. The composition for treating kidney deficiency according to claim 1, wherein the oyster peptide has a small molecule content of 65 wt% or more.
4. The composition for treating kidney deficiency according to claim 1, wherein the effective ingredients of the traditional Chinese medicine comprise the following raw materials in parts by weight: 40 parts of epimedium extract, 10 parts of American ginseng extract, 5 parts of cynomorium songaricum extract, 5 parts of cistanche extract, 5 parts of morinda officinalis extract and 5 parts of polyrhachis vicina extract.
5. The composition for treating kidney deficiency according to claim 1, wherein the effective ingredients of the traditional Chinese medicine comprise the following raw materials in parts by weight: 30 parts of epimedium extract, 5 parts of American ginseng extract, 2 parts of cynomorium songaricum extract, 2 parts of cistanche extract, 2 parts of morinda officinalis extract and 2 parts of polyrhachis vicina extract.
6. The composition for treating kidney deficiency according to claim 1, wherein the effective ingredients of the traditional Chinese medicine comprise the following raw materials in parts by weight: 60 parts of epimedium extract, 20 parts of American ginseng extract, 10 parts of cynomorium songaricum extract, 10 parts of cistanche extract, 10 parts of morinda officinalis extract, 10 parts of polyrhachis vicina extract and 80 parts of oyster peptide.
7. The composition for treating kidney deficiency according to claim 1, wherein the effective ingredients of the traditional Chinese medicine comprise the following raw materials in parts by weight: 45 parts of epimedium extract, 12 parts of American ginseng extract, 6 parts of cynomorium songaricum extract, 6 parts of cistanche extract, 6 parts of morinda officinalis extract, 6 parts of polyrhachis vicina extract and 55 parts of oyster peptide.
8. The composition for treating kidney deficiency according to claim 1, wherein the extraction ratio of epimedium extract, cynomorium songaricum extract, cistanche extract, morinda officinalis extract and polyrhachis vicina extract is 10: 1; the content of panaxoside in the American ginseng extract is more than or equal to 80 wt%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911193077.4A CN110721306A (en) | 2019-11-28 | 2019-11-28 | Composition for treating kidney deficiency |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911193077.4A CN110721306A (en) | 2019-11-28 | 2019-11-28 | Composition for treating kidney deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110721306A true CN110721306A (en) | 2020-01-24 |
Family
ID=69225753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911193077.4A Pending CN110721306A (en) | 2019-11-28 | 2019-11-28 | Composition for treating kidney deficiency |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110721306A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1363385A (en) * | 2002-01-11 | 2002-08-14 | 王京苏 | Chinese-medicine prescription and process for preparing medicine wine |
| CN1647672A (en) * | 2005-02-17 | 2005-08-03 | 金益泉 | Tonifying kidney health tea and its preparing method |
| CN103040950A (en) * | 2012-12-20 | 2013-04-17 | 苏州天南星生物科技有限公司 | Compound preparation of traditional Chinese medicine |
| CN103055109A (en) * | 2012-12-18 | 2013-04-24 | 苏州天南星生物科技有限公司 | Chinese medicinal preparation |
| CN108283701A (en) * | 2018-04-12 | 2018-07-17 | 李军 | A kind of drug and preparation method thereof for promoting male's sexual and treating impotence |
| CN110140960A (en) * | 2019-06-03 | 2019-08-20 | 宝健（北京）生物技术有限公司 | A kind of improvement male erectile dysfunction, antifatigue composition and preparation, drink |
-
2019
- 2019-11-28 CN CN201911193077.4A patent/CN110721306A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1363385A (en) * | 2002-01-11 | 2002-08-14 | 王京苏 | Chinese-medicine prescription and process for preparing medicine wine |
| CN1647672A (en) * | 2005-02-17 | 2005-08-03 | 金益泉 | Tonifying kidney health tea and its preparing method |
| CN103055109A (en) * | 2012-12-18 | 2013-04-24 | 苏州天南星生物科技有限公司 | Chinese medicinal preparation |
| CN103040950A (en) * | 2012-12-20 | 2013-04-17 | 苏州天南星生物科技有限公司 | Compound preparation of traditional Chinese medicine |
| CN108283701A (en) * | 2018-04-12 | 2018-07-17 | 李军 | A kind of drug and preparation method thereof for promoting male's sexual and treating impotence |
| CN110140960A (en) * | 2019-06-03 | 2019-08-20 | 宝健（北京）生物技术有限公司 | A kind of improvement male erectile dysfunction, antifatigue composition and preparation, drink |
Non-Patent Citations (4)
| Title |
|---|
| 何金铠等: "《新编老年百科全书》", 31 May 1993, 中国人事出版社 * |
| 宋敬东等: "《养生堂《本草纲目》中药养生速查全书》", 30 September 2013, 天津科学技术出版社 * |
| 张伦等: "《智者的医生就是自己 张伦谈保健》", 30 November 2017, 河北科学技术出版社 * |
| 黄岑汉等: "《民族医药与方剂学》", 30 September 2016, 广西科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105663607B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN104208302A (en) | Fructus rosae laevigatae healthy oral solution for reducing blood fat and preparation method thereof | |
| CN103194360A (en) | Medicinal liquor with healthcare function as well as preparation method and application thereof | |
| WO2006076844A1 (en) | Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof | |
| CN104288461A (en) | Ginseng cornu cervi tea traditional Chinese medicine decoction piece combined preparation, as well as preparation method and combined package thereof | |
| CN102526326B (en) | Traditional Chinese medicine for treating postmenopausal osteoporosis and preparation method thereof | |
| CN104958607A (en) | Traditional Chinese medicine composition for treating burning mouth syndromes of climacteric women and preparation method thereof | |
| CN104305453A (en) | American ginseng compounded anti-fatigue sports health beverage | |
| CN101507776B (en) | Traditional Chinese medicine preparation for treating kidney deficiency, waist and knees soreness and preparation method thereof | |
| CN104825914A (en) | Traditional Chinese medicinal preparation for assisted treatment of breast cancer | |
| CN107188984B (en) | Polysaccharide composition and preparation method and application thereof | |
| GB2581592A (en) | Preparation procedure for panax notoginseng medicinal liquor for oral administration for treating rheumatic ostalgia | |
| CN103432192A (en) | Composition with slimming function | |
| CN103330837B (en) | Traditional Chinese medicine composition for curing osteoporosis of menopausal women | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN102784230B (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN104548049A (en) | Traditional Chinese medicine composition for treating senile osteoporosis and preparation method thereof | |
| CN104524174A (en) | Traditional Chinese medicine composition for treating rheumatic arthralgia and preparation method thereof | |
| CN102048913B (en) | Traditional Chinese medicine preparation for treating climacteric syndrome and preparation method thereof | |
| CN103520302A (en) | Sea-buckthorn leaf anti-fatigue capsule and preparation method thereof | |
| CN110721306A (en) | Composition for treating kidney deficiency | |
| CN104840902A (en) | Traditional Chinese medicine preparation for treating ovarian tumor | |
| CN101816708B (en) | Chinese medicinal composition for curing rheumatism and preparation method thereof | |
| CN101284059A (en) | Chinese medicinal materials preparation for reinforcing the spleen and kidney and curing the chronic nephritis | |
| CN105250665A (en) | Traditional Chinese medicine composition with effect of improving erectile dysfunction and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200124 |